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OBJECTIVES The aim of this study was to determine whether in patients with congestive heart failure
(CHF) a distensibility (Dist) reduction: 1) similarly occurs in different arteries; 2) is related
to CHF severity; and 3) is reversible with treatment.
BACKGROUND Several studies suggest that CHF is accompanied by a reduced arterial Dist.
METHODS We measured diameter in radial artery, carotid artery (CA) and abdominal aorta (AO) by
echotracking. Distensibility was obtained by relating it to blood pressure. Data were collected
in 30 patients with CHF (New York Heart Association functional class I to III) under
standard treatment with diuretic, digitalis and angiotensin-converting enzyme (ACE)
inhibitor in whom CHF severity was assessed by maximum oxygen consumption (VO2max)
percentage and in 30 age- and gender-matched controls. Patients with CHF were then
randomized to maintain standard treatment (n  10), double the ACE inhibitor dose (n 
10) or add an angiotensin II antagonist (n  10) and restudied after two months.
RESULTS Distensibility was markedly reduced in the CHF group in all three vessels (p 0.01), CA and
AO Dist being related to CHF severity (p  0.05). After two months, Dist did not change
in the group maintained under standard treatment, but it increased significantly (p  0.05)
and similarly when the ACE inhibitor dose was doubled or an angiotensin II antagonist was
added.
CONCLUSIONS Congestive heart failure is characterized by a reduction of Dist of large-elastic and
middle-sized muscular arteries. The reduction of large-elastic artery Dist is related to the
CHF severity. These alterations can be reversed by drugs, effectively interfering with the
renin-angiotensin system either at the ACE or at the angiotensin receptor level. (J Am Coll
Cardiol 2002;39:1275–82) © 2002 by the American College of Cardiology Foundation
Several cardiovascular diseases are characterized by a re-
duced distensibility (Dist) of large arteries (1–11). This has
undesirable consequences because a reduction of arterial
Dist leads to: 1) an increase in arterial impedance and, thus,
in cardiac afterload; 2) a reduction in diastolic pressure and,
thus, in perfusion of organs such as the heart; and 3) an
acceleration of atherosclerosis due to an increase in systolic
and pulse pressure and to a greater traumatic effect on the
vessel walls (1–11). It has been suggested that congestive
heart failure (CHF) is associated with a reduction of arterial
Dist (12–16). However, information on this phenomenon is
largely incomplete. For example, no data have been ob-
tained on whether a reduction of arterial Dist occurs
similarly or differently in large-elastic and smaller muscle-
type arteries. Furthermore, whether the reduction of arterial
Dist relates to the heart failure severity is unknown. Finally,
it is also not known whether the arterial stiffening that
characterizes heart failure is reversible with different drug
approaches that interfere with the renin-angiotensin system.
In the present study we have addressed these issues by
measuring middle-sized and large-elastic artery Dist in
controls and in patients with CHF of different severity
before and after two months of a standard therapy
(angiotensin-converting enzyme [ACE] inhibitor, diuretic
and digitalis) and therapy based on doubling the dose of the
ACE inhibitor or associating an angiotensin type 1 receptor
antagonist to the low-dose ACE inhibitor.
METHODS
Subjects. We investigated 60 subjects. Thirty subjects
(CHF: 27 men; age: 60.4  1.4 years) were selected on a
consecutive basis if they had: 1) age 75 years; 2) chronic
heart failure belonging to New York Heart Association
functional class I (n  10), II (n  13) or III (n  7) with
either an ischemic (n  20) or nonischemic (n  10) origin;
3) no major valvular abnormalities; 4) a left ventricular
ejection fraction 40% (as described in the following text);
5) a standard medical treatment (diuretic, digitalis and
enalapril at a dose 20 mg daily) stable for at least three
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months; 6) no hemodynamically significant atherosclerotic
carotid, femoral or aortic lesions (echocolor-Doppler exam-
ination), no chronic arrhythmias, no major disease besides
heart failure and no chronic treatment with drugs other than
those mentioned in the preceding text; and 7) an adequate
ultrasonographic window for visualization of the abdominal
aorta (AO) (as described in the following text). The
remaining 30 subjects (controls: 28 men; age: 56.9 
1.5 years) were age-matched normotensive healthy individ-
uals. Two patients with CHF and three control subjects
were smokers. All subjects agreed to participate in the study
after being informed of its nature and purpose. The protocol
of the study was approved by the Ethics Committee of our
hospital.
Radial artery (RA) Dist and wall thickness (WT). Radial
artery diameter and WT were measured by an A-mode
ultrasonic device (NIUS 02, Omega, Bienne, Switzerland)
(17). Briefly, a highly focalized transducer operating at a
frequency of 10 MHz was stereotaxically positioned over the
RA using a gel as a medium. With the subject supine and
the arm immobile at the heart level, the transducer was
oriented perpendicularly to the longitudinal axis of the
vessel based on the acoustic Doppler signal. After switching
to A-mode, the echocardiography beams corresponding to
the posterior lumen-intima and media-adventitia interfaces
were visualized on a computer screen, and RA WT was
measured as the distance between the inner and outer wall
echoes (18). The back-scattered echoes from the inner
posterior and anterior wall of the artery were also visualized
and electronically digitized (analogic/digital fast transducer)
to allow internal diameter variations to be derived at 50 Hz
with a spatial dynamic resolution of 0.0025 mm (17,18).
A photopletysmographic system (Finapres 2003, Ohm-
eda, Englewood, Colorado) allowed blood pressure (BP) to
be concomitantly recorded at 50 Hz from a finger ipsilateral
to the RA examined, with an accuracy similar to intra-
arterial BP recording (19). The concomitant acquisition of
continuous diameter and BP signals allowed the calculation
of diameter across the diastolic-systolic BP range. The
diameter/BP curve was analyzed according to its fitting with
the arctangent model of Langewouters and then cross-
sectional Dist derived (cross-sectional compliance  vessel
area) (20).
Carotid artery (CA) Dist, WT and AO Dist. With the
subject supine and the neck in partial extension, the diam-
eter motion of the right common CA was measured 2 cm
below the CA bifurcation by a B-M mode echo-tracking
device based on Doppler shift (Wall Track System, PIE
Medical, Maastricht, the Netherlands) and on a transducer
operating at a frequency of 7.5 MHz (21). The transducer
was manually oriented perpendicularly to the longitudinal
axis of the vessel under B-mode and Doppler guidance.
After switching to A-mode, the back-scattered echoes from
the anterior and posterior CA walls were visualized and the
corresponding radiofrequency signal tracked to allow the
digitalized signal of the internal diameter variations to be
derived at 50 Hz. The spatial resolution was 300 m (21).
Blood pressure was measured from the brachial artery at the
same time of the ultrasound evaluation via a semiautomatic
device (Dinamap 1846 SX/SXP, Critikon, Chatenay Ma-
labry Cedex, France), and CA Dist was derived according to
the following formula (21):
Dist  2  Ds  Dd / Dd / PP
where Ds is the systolic diameter, Dd is the diastolic
diameter and PP is the corresponding pulse pressure (sys-
tolic BP  diastolic BP, average of three measurements).
The same procedure with a 3.5 MHz transducer was
employed to measure the diameter motion of the subdia-
phragmatic portion of the aorta, 2 to 3 cm above the origin
of the celiac plexus and to calculate AO Dist (21,22). For
technical reasons, however, no measurement of AO WT
could be reliably made. Carotid artery intima-media WT
was measured at a posterior wall site located 3 cm below
bifurcation through an ultrasonographic device (Hewlett
Packard Sonos 5500, Palo Alto, California). Measurements
were obtained by first scanning the artery in B-mode, then
freezing the digitized image in M-mode and finally tracking
the inner ipoechogenic and the middle anechogenic layers
(23).
All RA, CA and AO measurements were made by a
single operator. The within-operator variability of RA, CA
and AO diameter measurements at diastole (i.e., the coef-
ficient of variation of the mean values of two measurements
performed at two different times) was on average 2.3%, 2.8%
and 3.9%, respectively. The within-operator variability for
RA and CA WT were 2.0% and 3.0%, respectively.
Additional evaluations. One week before the study, each
subject underwent a standard echocardiocolor-Doppler to
obtain clinical information on left ventricular end-diastolic
diameter, left ventricular WT (septal plus posterior wall),
early and atrial transmitral flow and left ventricular ejection
fraction (Simpson formula). In addition, each patient with
CHF underwent two cardiopulmonary stress tests (at a one
week interval) with a cycloergometer ramp protocol (10
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANOVA  analysis of variance
AO  abdominal aorta
BP  blood pressure
CA  carotid artery
CHF  congestive heart failure
Dd  diastolic diameter
Dist  distensibility
Ds  systolic diameter
E/A  ratio between early and atrial transmitral
peak flow
RA  radial artery
VO2  volume of oxygen consumption
VO2max  maximum oxygen consumption
WT  wall thickness
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W/min) using a breath-by-breath volume of oxygen con-
sumption (VO2) and CO2 sampling for continuous gas
analysis, averaging expiratory data over 15-s periods and
calculating the maximum oxygen consumption (VO2max)
(%) during the test (24). The maximal exercise time was also
calculated. The VO2max and maximal exercise time were
obtained also after two months of therapy.
In each subject, BP was measured also by a mercury
sphygmomanometer, taking the first and fifth Korotkoff
sounds to identify systolic and diastolic values, respectively.
Heart rate was derived continuously from the finger pressure
signal as the reciprocal of the pulse interval between
consecutive beats. A venous blood sample was obtained after
a 30-min supine position and used (after storage at 80°) to
measure plasma-renin activity (radioimmunoassay).
Protocol and data analysis. Each subject was asked to
come to the outpatient clinic of the San Gerardo Hospital in
the morning after a 12-h abstinence from alcohol, caffeine
consumption and cigarette smoking. The study (which
began 3 h after a light meal) had the following protocol: 1)
BP was measured three times by mercury sphygmomanom-
eter with the subject in the sitting position; 2) the subject
was placed supine in a quiet room at a constant temperature
(21°C) and fitted with the finger BP and the RA echo-
tracking devices; 3) after a 15-min resting interval, finger
BP, heart rate and RA diameter were continuously mea-
sured for 15 min; 4) RA echo-tracking device was discon-
nected, the semiautomatic BP measuring device was placed
on the brachial artery, and the probe for CA evaluation was
positioned on the neck; 5) five 6-s acquisitions of CA
diameter throughout the cardiac cycle were obtained during
a 10-min period together with semiautomatic BP measure-
ments; 6) the probe for evaluation of the AO was posi-
tioned; 7) five 6-s acquisitions of the AO diameter through-
out the cardiac cycle were obtained during a 10-min period
together with semiautomatic BP measurements.
The above-mentioned measurements were obtained in
the same fashion after two months during which the
patients with CHF had been randomly assigned to: 1)
continuation of the previous standard therapy (10 patients);
2) modification of the previous therapy by increasing the
dose of enalapril up to 40 mg daily (10 patients); and 3)
modification of the previous therapy by adding losartan
50 mg daily (10 patients). Treatment was continued for two
months. Compliance to treatment was checked by pill
counting. Vascular measurements were made by operators
unaware of therapy assignation.
In each subject and for each study session, the sphygmo-
manometric and Dinamap BP values were averaged. In the
baseline condition, RA diameter and Dist/BP curves were
obtained by averaging data from five periods of 30 s each,
taken at 2-min intervals. The area under the RA Dist/BP
curve was corrected for pulse pressure and used as a single
integrated Dist value, which was called “operative” RA Dist
index. Comparisons between different groups and condi-
tions were also made by using the portion of the curve
having the same BP range, that is, the isobaric RA Dist
index (25). Carotid artery and AO diameter and Dist were
obtained by averaging data from the five 6-s acquisition
periods. Radial artery WT was measured over a 30-s period,
based on the ultrasound image.
Results from individual subjects were averaged and shown
as means  SE, separately for the control group, the CHF
group as a whole and the CHF groups under different
treatments. The statistical significance of the differences in
mean values was assessed by two-way analysis of variance
(ANOVA) and ANOVA for repeated measurements (pe-
riod and group, interactions, Stat View software, Abacus
Concepts Inc.). The two-tailed t test for paired and un-
paired observations was used (with the Bonferroni correc-
tion for multiple comparisons) to locate the statistical
significance of between-group differences. Data were also
analyzed by univariate regression taking Dist or WT as the
dependent variables and echocardiographic, laboratory or
ergospirometric variables as the independent ones. Signifi-
cant correlations were then tested by multivariate analysis. A
p value 0.05 was taken as the minimum level of statistical
significance.
RESULTS
Table 1 shows that, compared with controls, patients with
CHF had a lower systolic BP and left ventricular ejection
fraction but a greater left ventricular end-diastolic diameter,
left ventricular WT, ratio between early and atrial transmi-
tral peak flow (E/A),CA and AO diameter. Heart rate was
Table 1. Hemodynamic Characteristics of Patients with CHF
and Controls
Control
(n  30)
Heart Failure
(n  30)
SBP (mm Hg) 136.0  3.6 * 120.5  3.8
DBP (mm Hg) 80.9  5.6 75.8  1.9
PP (mm Hg) 55.0  3.2 45.2  2.5
SBP Din (mm Hg) 128.5  3.6 118.6  3.2
DBP Din (mm Hg) 75.0  1.7 69.5  1.6
PP Din (mm Hg) 53.5  2.0 49.1  1.5
HR (beats/min) 66.8  2.4 69.6  2.8
LVEDD (mm) 50.8  1.3 † 66.8  1.2
LVWT (mm) 18.2  0.3 * 20.8  0.5
LVEF (%) 67.4  2.8 † 31.2  0.8
E/A 1.1  0.1 * 1.4  0.2
PRA (pg/ml) 1.0  0.6 * 7.2  1.5
VO2 max (%) — 66.6  3.0
Max Ex Time (min) — 8.7  0.6
RA diameter (mm) 2.5  0.07 2.7  0.09
CA diameter (mm) 7.3  0.14 † 8.1  0.5
AO diameter (mm) 16.2  0.3 † 18.1  0.5
RA Dist Isob (1/mm Hg 103) 0.7  0.06 * 0.4  0.05
*p  0.05; †p  0.01. Data are shown as means  SE.
AO  abdominal aorta; CA  carotid artery; CHF  congestive heart failure;
DBP  diastolic blood pressure; Din  Dinamap; Dist.  distensibility; E/A  ratio
between early and atrial transmitral peak flow; Ex  exercise; HR  heart rate;
Isob  isobaric; LVEDD  left ventricular end-diastolic diameter; LVEF  left
ventricular ejection fraction; LVWT  left ventricular wall thickness; PP  pulse
pressure; PRA  plasma renin activity; RA  radial artery; SBP  systolic blood
pressure.
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similar in the two groups, whereas the CHF group showed
a much greater plasma renin activity than controls.
As shown in Figure 1 and Table 1, in all three vessels the
operative and isobaric RA Dist values were markedly
smaller in the former than in the latter group, the difference
being more marked for CA and AO and always statistically
significant. In the RA, the reduced Dist of CHF was visible
through the systolic-diastolic pressure range (Fig. 2). The
reduced Dist of CHF was accompanied by a significantly
greater WT both in the thinner RA and in the thicker CA.
Radial artery and CA WT showed an inverse relationship
with the respective Dist values (0.38 and 0.32, p 
0.01). Radial artery Dist was not related to CA and AO
Dist, which were, on the other hand, positively related to
each other (r  0.51, p  0.01). There was also a positive
relationship between CA and AO Dist and VO2max (r 
0.45 and 0.41, p  0.01) or E/A values (r  0.51 and 0.62,
p  0.01) but not with left ventricular ejection fraction.
Table 2 shows the data obtained in the three groups that
underwent different treatments for two months. Compared
with the initial values, in no group did BP, heart rate, left
ventricular ejection fraction, left ventricular end-diastolic
diameter, left ventricular WT or E/A show any significant
change. In each group VO2max percentage was also not
significantly different from baseline. Maximal exercise time
significantly increased both after the two months of the
greater dose ACE inhibitor administration and after the
two months of administration of the ACE inhibitor plus
angiotensin II antagonist. Plasma-renin activity was un-
changed in the group with unchanged treatment and not
significantly increased in the group given an ACE inhibitor
at a greater dose or the lower dose of ACE inhibitor plus the
angiotensin II receptor antagonist. No treatment modified
diameter and WT. In contrast, while in the group kept on
previous treatment, Dist also did not show any modification
in the groups given either the ACE inhibitor at the greater
dose or the low-dose ACE inhibitor plus the angiotensin II
receptor antagonist; Dist showed an increase that was
significant also when tested by ANOVA two-way analysis
for repeated measurements (main, period effect 0.01, inter-
action NS) in all three arteries (Fig. 3). In the RA this was
the case, also when isobaric Dist was considered.
DISCUSSION
Arterial stiffening in CHF. In our patients with CHF,
arterial Dist was markedly less than in age-matched controls
both at the level of the RA and at the level of the CA and
the AO. Furthermore, the reduction of CA and AO Dist
was directly related to an objective measure of the severity of
heart failure such as the VO2max estimated by cardiopul-
monary stress test. Finally, the reduction of RA and CA
Dist of CHF was accompanied by, and correlated with, an
increase in WT. This provides an answer to several ques-
tions that were addressed by our study. Namely, in heart
failure either muscle-type middle-size arteries and larger
elastic-type arteries are characterized by a clear-cut stiffen-
ing, which implies that in this condition arterial mechanical
properties are impaired throughout the arterial tree. Sec-
ondly, in the large elastic arteries (which account for the
larger portion of overall arterial Dist), this impairment is
related to the severity of heart failure, which implies that the
arterial stiffening of heart failure is not an all or none but
rather a gradual phenomenon. And thirdly, because of the
concomitant increase in arterial WT, the stiffening can be
ascribed to an alteration of the composition of the vessel
wall, that is, it can be accounted for, at least in part, by a
structural factor (26).
Effects of treatment on arterial stiffness. In a previous
study we have shown that adding an ACE inhibitor to a
treatment regimen based on diuretics and digitalis increased
RA Dist (27). In the present study patients were already
under treatment with diuretics, digitalis and an ACE
inhibitor. The novel finding, however, is that when treat-
ment was modified by either doubling the ACE inhibitor
dose or by adding to the treatment regimen an angiotensin
II antagonist, RA Dist was further improved, the change
being significant also when tested by ANOVA for repeated
measures (main effects and interactions). Furthermore, an
improvement was seen also in the Dist of larger more elastic
vessels such as AO and CA. Thus, a more effective blockade
of the renin-angiotensin system has favorable consequences
on impaired arterial mechanical properties of CHF. This is
the case regardless of whether the more effective blockade is
obtained by enhancing the ACE inhibitory effect on forma-
tion of angiotensin II or by preventing the action of this
substance at the receptor level.
Methodologic aspects of Dist measurement. Several
other findings deserve to be mentioned. One, in our study
AO and CA Dist were measured by the changes in vessel
diameter induced by pulse pressure changes, which were
quantified in the brachial artery. Although being a com-
monly used approach, this represents a limitation because,
ideally, vessel diameter and BP changes should be measured
at the same vascular site (2,4,6,7,11,15). However, this
cannot be obtained for the AO unless invasive (and hardly
feasible) BP measurements are employed. It is also difficult
to be obtained for the CA because: 1) patients with CHF
cannot easily sustain the relatively prolonged vessel com-
pression and breath-holding procedures that are necessary
for direct assessment of CA pulse pressure through tonom-
etry; and 2) this assessment is not devoid of inconveniences,
among which is limited reproducibility (28). More impor-
tantly, although the pulse pressure modification along the
arterial tree has not been thoroughly investigated in patients
with CHF, it is unlikely this condition could be character-
ized by a greater difference between values measured pe-
ripherally and more centrally and, thus, by a greater than
normal attenuation in CA and AO pulse pressure that could
have been responsible for a reduced excursion of vessel
diameter. First, differences between central and peripheral
pulse pressure are more evident during vasodilation, that is,
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Figure 1. Radial artery (RA) and carotid artery (CA) wall thickness and RA, CA and abdominal aorta distensibility in control subjects (n  30) and in patients with congestive heart failure (n  30). Data
are shown as mean  SE. Open bar  controls (n  30); hatched bar  heart failure (n  30).
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conditions opposite of that typical of CHF, which is
characterized by an increase in vascular resistance (29).
Second, in our patients with CHF, a reduced Dist was
documented also in the RA whose diameter changes were
quantified for nearby measured changes in BP. We can,
therefore, substantially conclude that there is a generalized
arterial stiffening in CHF, which can be improved by the
treatments we employed.
Arterial stiffness in CHF: possible mechanisms. In pa-
tients with CHF, CA and AO Dist correlated in a relatively
close fashion both to each other and to the E/A value while
showing no relation with RA Dist. This suggests that after
cardiac pump failure there might be a nonuniform progres-
sion of arterial stiffening in smaller and larger arteries. It also
suggests, however, that the stiffening progresses in a rather
uniform fashion throughout the large elastic portion of the
arterial tree and that this progression reflects a similar
progression of the stiffening in the heart (30).
Our results, however, do not clarify the nature of the
structural alteration that leads to the arterial stiffening of
patients with CHF. We can speculate that in the vessel wall
of these patients the less extensible tissue (e.g., collagen)
grows more than the more extensible one (elastin and
smooth muscle), presumably because of the influence of the
variety of growth factors (e.g., increase in norepinephrine,
increase in endothelins and reduction in nitric oxide secre-
tion, etc.) whose circulating and tissue concentration is
increased when the cardiac pump fails (31–33). We can also
speculate, however, that the arterial stiffening of CHF is just
vascular “waterlogging,” that is, an increase within the vessel
wall of “incompressible” water due to sodium retention
(34,35). We cannot, however, exclude that functional fac-
tors are additionally involved because “growth” substances
that can alter tissue composition of the vessel wall can in
many instances also powerfully contract the smooth muscle
cells that can be found both in muscle-type arteries and
(although to a lesser extent) in elastic-type ones, with an
increase in vessel elastic modulus with respect to the
condition in which smooth muscle is relaxed. Indeed, the
exclusive participation of structural factors to the reduction
of Dist seen in CHF is made unlikely both by the observa-
tions made in a previous study and data obtained in the
present study. In a previous study on CHF we have shown
RA Dist to be increased after four to eight weeks of
administration of an ACE inhibitor (27). This may be too
short a time for major structural changes to take place. In
the present study we have seen the increase in CA and RA
Dist after two months of treatment to be associated with no
change in arterial WT. This makes it possible that a pulse
pressure independent functional factor such as reduction of
Figure 2. Radial artery (RA) distensibility-pressure curves in the control
and congestive heart failure groups of Figure 1. Open circle  controls,
n  30; open square  heart failure, n  30.
Table 2. Effects of Treatment Modifications in Patients with CHF
T Unchanged
(n  10)
T Modified
(ACEI Doubled)
(n  10)
T Modified
(ACEI Unchanged  ATA)
(n  10)
B T B T B T
SBP (mm Hg) 117.3  4.3 114.0  7.9 128.8  6.9 122.4  3.5 123.9  3.6 118.3  4.6
DBP (mm Hg) 75.8  2.7 72.7  3.9 74.9  2.8 72.3  3.9 77.8  3.4 74.3  2.9
HR (beats/min) 70.3  2.7 72.5  3.2 67.5  5.2 64.3  4.1 69.3  4.2 71.3  4.8
LVEDD (mm) 67.4  2.3 66.1  1.8 65.9  3.7 63.4  4.7 68.4  2.7 66.3  3.1
LVWT (mm) 20.5  0.8 21.0  1.1 20.7  0.9 21.4  0.9 20.3  0.9 21.1  0.9
LVEF (%) 31.2  0.4 31.9  2.3 31.7  0.9 34.2  2.1 30.8  1.9 34.8  1.9
E/A 1.8  0.5 1.6  0.5 1.3  0.6 1.4  0.4 1.5  0.4 1.1  0.2
PRA (pg/ml) 6.5  2.2 6.7  1.8 7.2  2.2 12.1  6.8 5.1  1.8 21.7  8.0
Max VO2max (%) 65.8  6.5 69.8  6.4 67.9  5.6 71.2  5.2 63.9  4.8 71.2  3.8
Max Ex Time (min) 8.5  1.2 8.6  1.1 8.5  0.8 * 9.4  0.6 9.2  1.3 * 10.4  0.8
AO diameter (mm) 17.0  0.9 17.3  1.6 18.0  1.0 16.3  1.2 19.2  1.0 * 15.7  1.0
CA diameter (mm) 7.7  0.4 7.9  1.0 8.5  0.4 8.4  0.5 8.1  0.4 8.0  0.4
RA diameter (mm) 2.47  0.08 2.52  0.09 2.56  0.18 2.52  0.16 2.62  0.14 2.73  0.15
RA WT (mm) 0.30  0.02 0.29  0.02 0.30  0.02 0.32  0.02 0.35  0.02 0.33  0.02
CA WT (mm) 0.78  0.05 0.82  0.06 0.99  0.11 1.02  0.13 0.99  0.12 0.96  0.11
RA Dist Isob (1/mm Hg 10-3) 0.39  0.06 0.41  0.07 0.38  0.04 * 0.69  0.09 0.45  0.07 * 0.78  0.08
*p  0.05. Data are shown as means  SE.
ACEI  ACE-inhibitor; ATA  angiotensin antagonist; B  baseline; T  treatment; WT  wall thickness; all other abbreviations as in Table 1.
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smooth muscle contraction within the arterial wall by
blockade of the renin-angiotensin system is also involved.
Clinical implications. Our results have clinical implica-
tions. First, the progressive reduction of Dist as CHF
becomes more severe implies a progressive increase in
arterial impedance and cardiac afterload when the ability of
the heart to face the need of a greater performance is
compromised. Second, the arterial stiffening of patients
with CHF also means a greater traumatic effect of intravas-
cular pressure on the vessel wall, with a greater chance of
damaging its endothelial and intimal-medial structure (1,2).
Third, the reduced Dist of the CA and the AO in patients
with CHF means a reduced ability of baroreceptors to sense
BP changes and, consequently, reflexively restrain sympa-
thetic tone, renin release and vasopressin release (36). The
arterial stiffening may, therefore, represent an important
mechanism involved in the neurohumoral activation of heart
failure. All these consequences can be favorably counter-
acted by treatments that block the renin-angiotensin system
and more so if the blockade is made highly effective by high
ACE inhibitor doses or by opposing the system at different
sites.
Fourth, the similar increase in Dist seen in patients taking
the ACE inhibitor/angiotensin II antagonist combination
and the ACE inhibitor alone at a greater dose speaks against
a specific advantage of blocking the renin-angiotensin sys-
tem at two different sites as compared with making the
blockade more effective at the ACE site only. With the
caution required by the limited number of patients studied,
this negative finding emphasizes that for a specific advan-
tage of an ACE inhibitor/angiotensin II antagonist combi-
nation the protocol of the study should include comparison
with subjects in which an ACE inhibitor is given at a greater
dose. This has rarely been done in studies claiming the
superiority of combining an ACE inhibitor with an angio-
tensin II antagonist over ACE inhibition alone.
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